Which patients are recommended to receive low‑dose aspirin therapy according to current guidelines?

Who Meets Guidelines for Aspirin Therapy

Aspirin therapy is definitively recommended for secondary prevention in patients with established atherosclerotic cardiovascular disease (ASCVD), while for primary prevention, it should only be considered in select adults aged 40-59 years with ≥10% 10-year ASCVD risk who have low bleeding risk—and is not recommended for adults ≥60 years or those at low cardiovascular risk. 1, 2, 3

Secondary Prevention (Established ASCVD)

Aspirin is strongly recommended for patients with documented atherosclerotic cardiovascular disease, including: 4, 1

• History of myocardial infarction
• Prior stroke or transient ischemic attack
• Peripheral vascular disease or claudication
• Prior coronary or vascular bypass procedure
• Documented angina

Dosing for secondary prevention: 75-162 mg daily (most commonly 81 mg in the U.S.) 4, 1

For patients with aspirin allergy in this setting, clopidogrel 75 mg daily should be substituted. 4

Primary Prevention (No Prior ASCVD)

Adults Aged 40-59 Years

Aspirin may be considered in this age group only if all of the following criteria are met: 2, 3

• 10-year ASCVD risk ≥10% (calculated using pooled cohort equations or validated risk calculator)
• Not at increased bleeding risk (see contraindications below)
• Patient willingness to take daily aspirin long-term

The 2019 ACC/AHA guidelines downgraded this to a Class IIb recommendation (may be considered) rather than routine use, reflecting that absolute benefits are small and comparable to bleeding risks. 2 The 2022 USPSTF guidelines similarly recommend individualized decision-making (Grade C recommendation). 3

Dosing for primary prevention: 75-100 mg daily (lower doses preferred to minimize bleeding risk) 1, 2

Adults Aged ≥60 Years

Aspirin should NOT be initiated for primary prevention in adults 60 years or older, as bleeding risks exceed cardiovascular benefits in this age group. 2, 3 The 2022 USPSTF issued a Grade D recommendation (recommends against) for initiating aspirin in this population. 3

Adults Aged <40 Years

Insufficient evidence exists to recommend aspirin for primary prevention in adults under 40 years. 2 Aspirin is contraindicated in those under 21 years due to Reye syndrome risk. 4

Special Population: Diabetes Mellitus

For patients with diabetes, aspirin recommendations have evolved significantly:

Aspirin may be considered in diabetic patients meeting these criteria: 4, 5

• Age ≥50 years (men) or ≥60 years (women)
• At least one additional major ASCVD risk factor:
  • Family history of premature ASCVD
  • Hypertension
  • Dyslipidemia
  • Smoking
  • Chronic kidney disease or albuminuria
• 10-year ASCVD risk >10%
• Not at increased bleeding risk

However, the 2019 Diabetes Care guidelines note that for patients over 70 years with diabetes, the balance favors greater risk than benefit, and aspirin is generally not recommended for primary prevention. 4

Aspirin should NOT be used in diabetic patients who are younger (<50 years men, <60 years women) with no additional risk factors, as bleeding risks outweigh benefits. 4, 5

Absolute Contraindications and High Bleeding Risk

Do not use aspirin in patients with: 4, 5, 6, 2

• History of gastrointestinal bleeding or active peptic ulcer disease
• History of hemorrhagic stroke
• Known aspirin allergy or hypersensitivity
• Active bleeding disorder or coagulopathy
• Thrombocytopenia
• Severe chronic kidney disease
• Concurrent anticoagulant therapy (warfarin, direct oral anticoagulants) without specific indication
• Concurrent use of NSAIDs or medications increasing bleeding risk
• Clinically active hepatic disease
• Age <21 years (Reye syndrome risk)

Role of Coronary Artery Calcium (CAC) Scoring

CAC scoring may help personalize aspirin decisions in primary prevention by identifying subclinical atherosclerosis: 7, 8

• CAC ≥100: May favor aspirin use (number needed to treat lower than number needed to harm)
• CAC ≥400: Stronger consideration for aspirin therapy
• CAC = 0: Aspirin generally not beneficial (number needed to harm exceeds number needed to treat)

The 2019 ACC/AHA guidelines mention CAC as a risk-enhancing factor that may inform aspirin decisions, though it is not required for decision-making. 2

Acute Coronary Syndrome (ACS)

For patients presenting with ACS, aspirin is mandatory: 1

• Loading dose: 162-325 mg orally (chewed, non-enteric coated for faster absorption)
• Maintenance dose: 75-100 mg daily (non-enteric coated)
• Continue indefinitely as secondary prevention

Dual antiplatelet therapy (aspirin plus P2Y12 inhibitor like clopidogrel, prasugrel, or ticagrelor) is required for at least 1 year post-ACS. 4, 1

Common Pitfalls

• Overuse in low-risk populations: Recent trials show no net benefit and potential harm in adults with <10% 10-year ASCVD risk or those ≥60 years for primary prevention. 2, 3
• Using high-dose aspirin unnecessarily: Doses >100 mg daily increase bleeding risk without additional cardiovascular benefit. 1, 2
• Ignoring bleeding risk assessment: Always evaluate for history of GI bleeding, concurrent medications, age >70 years, and renal disease before initiating aspirin. 4, 2
• Assuming all diabetic patients need aspirin: Only those with elevated ASCVD risk and age criteria benefit; younger diabetics without additional risk factors should not receive aspirin. 4, 5

Pregnancy Considerations

Low-dose aspirin (81 mg daily) is recommended in pregnant women at high risk for preeclampsia, initiated between 12-28 weeks gestation (optimally before 16 weeks) and continued until delivery. 9 This indication is distinct from cardiovascular prevention.